HMG is the outlier in this batch: unlike the SARMs above, it is a **purified, approved
gonadotropin preparation** with a long clinical record. The honest framing here is the reverse of
the SARMs — the evidence is strong, and the nuance is about formulation and context of use.
Chemical identity & structure.
HMG (human menopausal gonadotropin), generic name menotropins, is a purified preparation of
gonadotropins extracted from the urine of postmenopausal women. It contains both
follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity (classically in
roughly 1:1 ratio), the latter often standardized with a small amount of hCG. It is a biological
protein-hormone preparation, not a synthetic small molecule or research peptide.
Mechanism of action.
FSH and LH are the pituitary gonadotropins that drive gonadal function. FSH stimulates follicular
development in the ovary and supports spermatogenesis (via Sertoli cells) in the testis; LH drives
ovulation and corpus-luteum function in women and testosterone production by Leydig cells in men.
HMG supplies both activities exogenously.
Key research findings.
HMG/menotropins are approved drugs (e.g. Menopur, Repronex and related products) with decades
of use in assisted reproduction — controlled ovarian stimulation for IVF and ovulation induction.
In men, gonadotropin therapy (HMG, often with hCG) has an established role in
hypogonadotropic-hypogonadism fertility research and treatment. This is a genuinely
well-evidenced agent, in contrast to most compounds in the research-peptide space.
The research / citation base.
The citation base is large and clinical: regulatory approvals, pharmacopoeial standards, and an
extensive reproductive-medicine literature. The key interpretive note is that this evidence is
about supervised fertility indications, which is a different context from the
testosterone-recovery framing sometimes seen in community settings.
The FDA-approved MENOPUR (menotropins) label specifies, for development of multiple follicles and pregnancy in ovulatory women as part of an ART cycle, a starting dose of 225 International Units administered subcutaneously daily beginning on cycle day 2 or 3 (DailyMed). The label limits dosage adjustments to no more often than every 2 days and to no more than 150 International Units per adjustment, caps daily doses at 450 International Units, and states that therapy is not to exceed 20 days.
HMG products are supplied as lyophilised powder with diluent. The MENOPUR label states that the lyophilized powder may be stored refrigerated or at room temperature (3° to 25° C/37° to 77°F) until dispensed (DailyMed).
Quality & sourcing notes.
Because HMG is a urine-derived biological, identity and potency standardization (IU of FSH/LH
activity) are the relevant quality measures, and approved products carry pharmacopoeial release
testing. Research-grade or non-pharmaceutical "HMG" without that standardization is a different
risk category — potency and purity cannot be assumed.
*Research-use note: This monograph is an educational summary of the published research literature.
Menotropins are approved fertility medicines used under medical supervision; this monograph is
research context only and is not medical advice or a usage recommendation.*
